TScan Therapeutics to Participate in Upcoming Investor Conferences

Core Insights - TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on T cell receptor (TCR)-engineered T cell (TCR-T) therapies for cancer treatment [2] - The company is participating in upcoming investor conferences, providing opportunities for engagement with investors [1] Company Overview - TScan Therapeutics is developing TCR-T therapies aimed at treating patients with hematologic malignancies and preventing relapse after allogeneic hematopoietic cell transplantation, specifically through the ALLOHA Phase 1 heme trial [2] - The company is expanding its ImmunoBank, a repository of therapeutic TCRs that target diverse cancer-related antigens, to offer customized multiplex TCR-T therapies for various cancers, as seen in the PLEXI-T Phase 1 solid tumor trial [2] Upcoming Events - TScan will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 5:35 p.m. ET [3] - The company will also present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 9:00 a.m. ET [3]